PEG-uricase in the management of treatment-resistant gout and hyperuricemia
- 14 August 2007
- journal article
- review article
- Published by Elsevier BV in Advanced Drug Delivery Reviews
- Vol. 60 (1), 59-68
- https://doi.org/10.1016/j.addr.2007.06.011
Abstract
No abstract availableThis publication has 57 references indexed in Scilit:
- Pharmacokinetics and pharmacodynamics of intravenous PEGylated recombinant mammalian urate oxidase in patients with refractory goutArthritis & Rheumatism, 2007
- Hyperuricemia and Incidence of Hypertension Among Men Without Metabolic SyndromeHypertension, 2007
- Using serum urate levels to determine the period free of gouty symptoms after withdrawal of long‐term urate‐lowering therapy: A prospective studyArthritis Care & Research, 2006
- Gout and the risk of acute myocardial infarctionArthritis & Rheumatism, 2006
- Maximizing Therapeutic Benefit of Rituximab: Maintenance Therapy Versus Re-Treatment at Progression in Patients With Indolent Non-Hodgkin's Lymphoma—A Randomized Phase II Trial of the Minnie Pearl Cancer Research NetworkJournal of Clinical Oncology, 2005
- Efficacy and safety of rasburicase, a recombinant urate oxidase (Elitek™), in the management of malignancy-associated hyperuricemia in pediatric and adult patients: final results of a multicenter compassionate use trialLeukemia, 2004
- Management of Acute and Chronic Gouty ArthritisDrugs, 2004
- Studies on antigenicity of the polyethylene glycol (PEG)-modified uricaseInternational Journal of Immunopharmacology, 1985
- FATAL STEVENS-JOHNSON SYNDROME IN A PATIENT ON CAPTOPRIL AND ALLOPURINOLThe Lancet, 1984
- Uricolytic Activity of Purified Uricase in Two Human BeingsScience, 1957